Online inquiry

IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6605MR)

This product GTTS-WQ6605MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets DPEP3 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001129758.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 64180
UniProt ID Q9H4B8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ6605MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15600MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ12092MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ15203MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ13349MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ7127MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FE 999302
GTTS-WQ6595MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DC-1728001
GTTS-WQ8533MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Hu5A8
GTTS-WQ2436MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 157
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW